Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EBT: 2011-2025

Historic EBT for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to $33.8 million.

  • Ani Pharmaceuticals' EBT rose 207.31% to $33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.5 million, marking a year-over-year increase of 773.73%. This contributed to the annual value of -$22.2 million for FY2024, which is 211.78% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' EBT stood at $33.8 million, which was up 221.14% from $10.5 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' EBT ranged from a high of $33.8 million in Q3 2025 and a low of -$31.5 million during Q3 2024.
  • Its 3-year average for EBT is $5.6 million, with a median of $5.2 million in 2023.
  • Per our database at Business Quant, Ani Pharmaceuticals' EBT plummeted by 26,000.00% in 2022 and then spiked by 1,051.59% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' EBT (Quarterly) stood at -$30.9 million in 2021, then surged by 81.43% to -$5.7 million in 2022, then surged by 116.53% to $947,000 in 2023, then plummeted by 1,553.22% to -$13.8 million in 2024, then skyrocketed by 207.31% to $33.8 million in 2025.
  • Its EBT was $33.8 million in Q3 2025, compared to $10.5 million in Q2 2025 and $20.0 million in Q1 2025.